Lumea wins 2026 MedTech Breakthrough award for biopsy technology

By AI, Created 5:16 PM UTC, May 18, 2026, /AGP/ – Lumea won the 2026 MedTech Breakthrough Award for Best New Biopsy Technology Solution, putting the digital pathology company alongside major medtech brands in a program that drew more than 5,000 nominations. The award spotlights Lumea’s biopsy handling system, which the company says reduces specimen errors and test cancellations tied to poor sample quality.

Why it matters: - The award gives Lumea validation in a crowded digital health market where biopsy handling can affect diagnosis quality, lab efficiency and patient outcomes. - Lumea’s technology is aimed at the pre-analytical step, where tissue can be damaged before pathology review and where errors can delay care or force repeat testing. - Clinical validation across more than two million specimens showed a 2.1x reduction in cancelled tests due to QNS or RNA degradation, an 83% reduction in collection containers per case and a 28% increase in core length.

What happened: - Lumea announced it won the “Best New Biopsy Technology Solution” award in the 2026 MedTech Breakthrough Awards program on May 14, 2026. - The MedTech Breakthrough Awards program received more than 5,000 nominations from digital health and medical technology companies worldwide. - MedTech Breakthrough selected Lumea from thousands of entries based on innovation, design, performance and market impact. - The winners list also included companies such as Medtronic, Boston Scientific and Thermo Fisher Scientific.

The details: - Lumea’s BxBoard replaces the standard formalin jar used for biopsy collection. - The BxBoard uses site-specific lanes to keep biopsy cores flat, straight and properly oriented during fixation and lab processing. - The system uses absorption fixation instead of traditional immersion fixation. - Lumea says that approach helps prevent autolysis and over-fixation common in high-volume specimen jars. - For urological diagnostics, the BxBoard preserves the proximal-versus-distal orientation of a core, which supports surgical planning. - A standard 12-core prostate biopsy that once required 12 separate jars and 12 separate labels can be consolidated into two BxBoards. - Lumea says that consolidation lowers the risk of mislabeling and specimen mix-ups at the point of care. - James Thackeray, Lumea’s CEO, said the formalin jar was designed long before digital pathology existed and that the BxBoard addresses a missing piece in the workflow. - Bianca Collings, Lumea’s chief marketing officer, said canceled tests are a patient outcome issue, not just a lab efficiency issue. - Lumea’s Viewer+ digital pathology platform has FDA 510(k) clearance for primary clinical diagnosis and CE marking under the EU’s In Vitro Diagnostic Regulation for clinical use across Europe. - Lumea has also been recognized by Inc. 5000, named to the Utah Business Fast 50 and previously honored as Healthcare Tech Innovator of the Year by Global Health and Pharma. - Lumea says it supports 40% of the U.S. outpatient prostate market and has delivered an 18.79% increase in cancer detection rates. - The company says it has national leadership in primary digital diagnostics across gastroenterology and dermatology. - More information is available in the company’s announcement and on its social channels: LinkedIn, Instagram, YouTube and X.

Between the lines: - The award highlights a shift in digital pathology from scanning slides to improving the tissue collection process that determines whether a sample is usable in the first place. - Lumea is positioning biopsy collection hardware as a clinical quality tool, not just a specimen container. - The competitive field and the long list of winners suggest the award is meant to signal broad market relevance, not a narrow niche win.

What’s next: - Lumea is likely to use the award to reinforce adoption of the BxBoard and its broader digital pathology workflow. - The company’s next growth story will depend on whether its clinical and operational results continue to translate into broader use across outpatient and specialty settings.

The bottom line: - Lumea’s award underscores a simple point: better pathology starts before the slide is ever digitized.